-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 16, Tianyan Pharmaceutical announced that the U.
ADG126 safe antibody can achieve specific activation in the tumor microenvironment, enhance therapeutic effect through strong clearance of regulatory T cells, and maintain physiological function through flexible ligand blockade
Using precise masking technology to cover the antigen-binding domain of antibodies, Tianyan's safe antibody technology can solve the safety and tolerability problems in many antibody therapies
The ADG126-P001 clinical trial is designed to evaluate the safety, tolerability and recommended dose of Phase II clinical trials of ADG126 in combination with pembrolizumab.
(Original abridged)